中藥注射劑（TCMIs）起效快、療效確切、臨床應(yīng)用廣泛，但其類過(guò)敏反應(yīng)（ARs）等不良事件已成為中藥安全性研究的熱點(diǎn)和難點(diǎn)。近年來(lái)，為加快推進(jìn)TCMIs安全性再評(píng)價(jià)，深入了解TCMIs相關(guān)ARs的癥狀特點(diǎn)、致敏成分、作用機(jī)制等，研究者采用體內(nèi)實(shí)驗(yàn)（ARs癥狀觀察法、伊文思藍(lán)藍(lán)染法、組織病理學(xué)檢查法）、體外實(shí)驗(yàn)（甲基四氮唑與細(xì)胞計(jì)數(shù)試劑盒-8法、染色法、膜黏連蛋白V結(jié)合法等）方法對(duì)ARs進(jìn)行了評(píng)估，可為建立可靠的評(píng)價(jià)方法提供依據(jù)，為臨床TCMIs相關(guān)ARs的早期識(shí)別、風(fēng)險(xiǎn)防控提供新思路。

Traditional Chinese medicine injections (TCMIs) have been widely used in clinical because of their rapid onset of action and precise efficacy, while their anaphylactoid reactions (ARs) and other adverse events have become a hot spot and a difficult area for safety research on traditional Chinese medicine. In recent years, in order to accelerate the safety re-evaluation of TCMIs and to gain a deeper understanding of the symptom characteristics, allergenic components and mechanisms of TCMIs-related ARs. The reseachers evaluated ARs using in vivo experiments (ARs symptom observation method, Evans blue staining method, histopathological examination method) and in vitro experiments (methyl tetrazolium and cell counting kit-8 method, staining method, membrane adhesion protein V binding method). It can provide a basis for establishing scientific and reliable evaluation methods, and provide new ideas for early identification, risk prevention and control of of clinical TCMIs-related ARs.

R969.3；R285.5

國(guó)家自然科學(xué)基金資助項(xiàng)目（82174069）；湖南省教育廳科學(xué)研究項(xiàng)目（21B0375）；湖南省衛(wèi)健委科研計(jì)劃課題（C202313057956）